Ardelyx (ARDX) Free Cash Flow Growth (3y) (2016 - 2026)
Ardelyx (ARDX) Free Cash Flow Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 31.42% |
| 10 | Ardelyx | 1.26 Bn | 1.02 Bn | 89.66 Mn | 10.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.33% |
| Dec 31, 2025 | 13.11% |
| Sep 30, 2025 | 26.16% |
| Jun 30, 2025 | 5.99% |
| Mar 31, 2025 | -11.98% |
| Dec 31, 2024 | 30.73% |
| Sep 30, 2024 | 26.21% |
| Jun 30, 2024 | 17.69% |
| Mar 31, 2024 | 7.27% |
| Dec 31, 2023 | 21.10% |
| Sep 30, 2023 | -2.82% |
| Jun 30, 2023 | 7.96% |
| Mar 31, 2023 | -21.52% |
| Dec 31, 2022 | 48.54% |
| Sep 30, 2022 | -7.05% |
| Jun 30, 2022 | -3.93% |
| Mar 31, 2022 | -17.38% |
| Dec 31, 2021 | -28.12% |
| Sep 30, 2021 | -9.09% |
| Jun 30, 2021 | -24.80% |